文献速递类风湿关节炎

巴瑞替尼治疗中重度类风湿关节炎长达6.5年的疗效:一项长期研究结果

Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: results of a long-term study.
PubMed 文献 · Rheumatology (Oxford) · 2024-01-01

该分析纳入三项已完成III期研究(RA-BEAM、RA-BUILD、RA-BEACON)及长期扩展研究RA-BEYOND的数据,评估巴瑞替尼4 mg或2 mg每日一次治疗对MTX、csDMARD或bDMARD应答不足的类风湿关节炎患者的长期疗效,最长随访至6.5年。结果显示,巴瑞替尼4 mg组在NRI/完成者分析中维持低疾病活动度和缓解,且耐受性良好。

要点

  • 巴瑞替尼4 mg在MTX-IR、csDMARD-IR和bDMARD-IR人群中均维持低疾病活动度至第340/336周。
  • 巴瑞替尼4 mg的缓解率在MTX-IR人群中最高,bDMARD-IR人群中较低。
  • 巴瑞替尼4 mg或2 mg治疗至6.5年耐受性良好。

核心结论

  • 巴瑞替尼4 mg或2 mg治疗至6.5年显示出疗效,SDAI、CDAI和DAS28-hsCRP评估的低疾病活动度/缓解结果维持稳定,与既往报告数据一致,且耐受性良好。

研究设计与样本

  • 分析三项已完成III期研究RA-BEAM(MTX-IR)、RA-BUILD(csDMARD-IR)和RA-BEACON(bDMARD-IR)及一项已完成长期扩展研究RA-BEYOND的数据。
  • 随访至6.5年,其中RA-BEAM为340周,RA-BUILD和RA-BEACON为336周。
  • 对每个人群进行完成者分析和无应答者插补(NRI)分析。

主要发现

  • 第340周或336周,巴瑞替尼4 mg组达到低疾病活动度(SDAI≤11)的比例按NRI/完成者分析分别为:MTX-IR 37%/83%,csDMARD-IR 35%/83%,bDMARD-IR 23%/73%。
  • 第340周或336周,巴瑞替尼4 mg组达到临床缓解(SDAI≤3.3)的比例按NRI/完成者分析分别为:MTX-IR 20%/40%,csDMARD-IR 13%/32%,bDMARD-IR 9%/30%。
  • 第340周或336周,巴瑞替尼4 mg组达到HAQ-DI≤0.5的比例按NRI/完成者分析分别为:MTX-IR 31%/51%,csDMARD-IR 25%/46%,bDMARD-IR 24%/38%。

关键数值与推荐

  • 低疾病活动度定义为SDAI≤11。
  • 临床缓解定义为SDAI≤3.3。
  • 身体功能定义为HAQ-DI≤0.5。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the long-term efficacy of once-daily baricitinib 4 mg or 2 mg in patients with active rheumatoid arthritis who had inadequate response (IR) to MTX, csDMARDs or bDMARDs. METHODS: Data from three completed phase III studies-RA-BEAM (MTX-IR), RA-BUILD (csDMARD-IR) and RA-BEACON (bDMARD-IR)-and one completed long-term extension study (RA-BEYOND) were analysed up to 6.5 years [340 weeks (RA-BEAM) and 336 weeks (RA-BUILD and RA-BEACON)]. Low disease activity (LDA) [Simplified Disease Activity Index (SDAI) ≤11], clinical remission (SDAI ≤3.3) and physical function [Health Assessment Questionnaire Disability Index (HAQ-DI) ≤0.5] were the main outcomes assessed. Completer and non-responder imputation (NRI) analyses were conducted on each population. RESULTS: At week 340 or 336, LDA was achieved in 37%/83% of MTX-IR, 35%/83% of csDMARD-IR and 23%/73% of bDMARD-IR patients treated with baricitinib 4 mg, assessed by NRI/completer analyses, respectively. Remission was achieved in 20%/40% of MTX-IR, 13%/32% of csDMARD-IR and 9%/30% of bDMARD-IR patients treated with baricitinib 4 mg, assessed by NRI/completer analyses, respectively. HAQ-DI ≤0.5 was reached in 31%/51% of MTX-IR, 25%/46% of csDMARD-IR and 24%/38% of bDMARD-IR patients treated with baricitinib 4 mg, assessed by NRI/completer analyses, respectively. CONCLUSION: Treatment with baricitinib 4 mg or 2 mg demonstrated efficacy up to 6.5 years with maintained LDA/remission results across SDAI, CDAI and DAS28-hsCRP consistent with previously reported data, and was well tolerated. TRIAL REGISTRATION: United States National Library of Medicine clinical trials database www.clinicaltrials.gov; RA-BEYOND; NCT01885078.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Caporali R, Taylor PC, Aletaha D, et al. Efficacy of baricitinib in patients with moderate-to-severe rheumatoid arthritis up to 6.5 years of treatment: results of a long-term study. Rheumatology (Oxford). 2024. PMID: 38258434. doi:10.1093/rheumatology/keae012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。